The estimated Net Worth of Mark Simon is at least $114 Tisíc dollars as of 18 October 2022. Mr. Simon owns over 125,000 units of Cabaletta Bio Inc stock worth over $29,820 and over the last 5 years he sold CABA stock worth over $0. In addition, he makes $83,822 as Independent Director at Cabaletta Bio Inc.
Mark has made over 1 trades of the Cabaletta Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 125,000 units of CABA stock worth $122,500 on 18 October 2022.
The largest trade he's ever made was buying 125,000 units of Cabaletta Bio Inc stock on 18 October 2022 worth over $122,500. On average, Mark trades about 20,833 units every 0 days since 2019. As of 18 October 2022 he still owns at least 7,000 units of Cabaletta Bio Inc stock.
You can see the complete history of Mr. Simon stock trades at the bottom of the page.
Mark J. Simon serves as Independent Director of the Company. He is a partner and co-founder of Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon serves on the board of directors of Sun Pharma Advanced Research Company Limited. He received his MBA from Harvard Business School and his B.A. from Columbia College.
As the Independent Director of Cabaletta Bio Inc, the total compensation of Mark Simon at Cabaletta Bio Inc is $83,822. There are 9 executives at Cabaletta Bio Inc getting paid more, with Anup Marda having the highest compensation of $1,528,630.
Mark Simon is 58, he's been the Independent Director of Cabaletta Bio Inc since 2018. There are 4 older and 9 younger executives at Cabaletta Bio Inc. The oldest executive at Cabaletta Bio Inc is Richard Henriques, 64, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... a James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
Cabaletta Bio Inc executives and other stock owners filed with the SEC include: